Literature DB >> 8863000

Review: treatment of schizophrenia. State of the art.

H J Möller1.   

Abstract

As a result of the multifactorial etiopathology of schizophrenia, a treatment strategy combining drug therapy with psychosocial measures is indicated. Depending on the stage of the disease and on the individual condition of the patient, the accent is set alternatively more on one approach or on the other. However, under aspects of symptom reduction and relapse prophylaxis, the therapy with neuroleptics plays the most important role. In order to keep their side effects to a minimum during acute and long term treatment, there is nowadays a trend towards administration of the lowest possible dose. Under this aspect, the use of so called atypical neuroleptics should be taken into consideration. The treatment of negative symptoms, especially in the context of chronic residual syndrome, is still a problem which hasn't been solved to satisfaction. Beside the use of atypical neuroleptics, treatment with antidepressives should be tried. During the long term relapse prophylactic treatment, it is important that not only the criterion "reduction of the relapse rate" but also that of individual risk/benefit relation be considered. Concerning psychosocial therapies, especially focused behavioural therapy approaches, for example educational programs and specific family therapeutical intervention following the high-EE-concept, as well as training of social and cognitive competences have proved useful beside supportive psychotherapy and the whole range of sociotherapeutical measures. However they need further evaluation before they get integrated in routine treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8863000     DOI: 10.1007/bf02190273

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  40 in total

1.  Observations on the dose regime of fluphenazine decanoate in maintenance therapy ofschizophrenia.

Authors:  D A Johnson
Journal:  Br J Psychiatry       Date:  1975-05       Impact factor: 9.319

2.  Dosage of haloperidol for schizophrenia.

Authors:  A Rifkin; S Doddi; B Karajgi; M Borenstein; M Wachspress
Journal:  Arch Gen Psychiatry       Date:  1991-02

3.  Changing patterns of neuroleptic dosage over a decade.

Authors:  G T Reardon; A Rifkin; A Schwartz; A Myerson; S G Siris
Journal:  Am J Psychiatry       Date:  1989-06       Impact factor: 18.112

4.  Are antipsychotic drugs interchangeable?

Authors:  G Gardos
Journal:  J Nerv Ment Dis       Date:  1974-11       Impact factor: 2.254

Review 5.  Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

Authors:  R J Baldessarini; B M Cohen; M H Teicher
Journal:  Arch Gen Psychiatry       Date:  1988-01

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 7.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

8.  A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.

Authors:  H J Möller; H Müller; R L Borison; N R Schooler; G Chouinard
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

9.  Treatment of schizoaffective disorders.

Authors:  P J Goodnick; H Y Meltzer
Journal:  Schizophr Bull       Date:  1984       Impact factor: 9.306

10.  Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion.

Authors:  G E Hogarty; C M Anderson; D J Reiss; S J Kornblith; D P Greenwald; C D Javna; M J Madonia
Journal:  Arch Gen Psychiatry       Date:  1986-07
View more
  3 in total

1.  Enhancement of executive functioning skills: an additional tier in the treatment of schizophrenia.

Authors:  Deana B Davalos; Mack Green; Daniel Rial
Journal:  Community Ment Health J       Date:  2002-10

2.  [Atypical antipsychotics in therapy refractory schizophrenia].

Authors:  I Schäfer; M Lambert; D Naber
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 3.  Carbamazepine for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John McGrath
Journal:  Cochrane Database Syst Rev       Date:  2014-05-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.